Evidence map›Paper›PMID 35476126›Full record

ArticleBlood advances2022

The contribution of rare copy number variants in FAS toward pathogenesis of autoimmune lymphoproliferative syndrome.

Kathleen Jevtich, Susan Price, Morgan Similuk, Elaine Kulm, Jia Yan, Michael Setzer, Leila Jamal, Luis M Franco, Rajarshi Ghosh, Magdalena Walkiewicz and 1 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Nature and nurture: understanding phenotypic variation in inborn errors of immunity.Frontiers in cellular and infection microbiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Kathleen JevtichNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Susan PriceNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Morgan SimilukNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Elaine KulmClinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD.
Jia YanNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-0506-5957
Michael SetzerNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Leila JamalNIH Clinical Center Department of Bioethics, National Institutes of Health, Bethesda, MD; and.ORCID 0000-0003-1132-2411
Luis M FrancoNational Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-0540-5942
Rajarshi GhoshNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Magdalena WalkiewiczNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
V Koneti RaoNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-7881-6902
National Institutes of Health · USFrederick National Laboratory for Cancer Research · USNational Institutes of Health Clinical Center · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
Central Sequencing InitiativeZICAI001244 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2019 to 2025
$24.0M
Clinical, Immunological and Genetic Analyses of ALPS and Related Immunedysregulatory DisordersZIAAI000732 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RAO, V KONETI · 2009 to 2025
$10.5M
Integrative genomic analysis of the human response to glucocorticoidsZIAAR041213 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI FRANCO, LUIS · 2020 to 2025
$4.8M
NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is characterized by chronic nonmalignant lymphadenopathy, splenomegaly, cytopenias, and other autoimmune manifestations. ALPS is caused by lymphocyte accumulation from defects in FAS-mediated apoptosis. Heterozygous germline or somatic pathogenic single nucleotide variants in FAS are the most common molecular etiology of ALPS. Through the Centralized Sequencing Program at the National Institute of Allergy and Infectious Diseases, we performed exome sequencing on subjects with a clinical diagnosis of ALPS, with a subset receiving copy number variant (CNV) analysis. In this cohort, we identified 3 subjects from unrelated families with CNVs at the FAS locus. One subject had a de novo ∼0.828 Mb copy number loss encompassing all of FAS. The second subject had a maternally inherited ∼1.004 Mb copy number loss encompassing all of FAS. The third subject had a paternally inherited ∼0.044 Mb copy number loss encompassing exons 7 through 9 of FAS. Subjects with deletions in FAS had clinical presentations and biomarker profiles similar to those with ALPS and with germline and somatic FAS variants. We demonstrate that CNV analysis should be pursued if there is clinical and biomarker evidence of ALPS because it can lead to a molecular diagnosis and appropriate treatment when FAS sequencing is inconclusive.

Indexed as

Autoimmune Lymphoproliferative SyndromeDNA Copy Number Variationsfas ReceptorHeterozygoteHumansSplenomegalyfas Receptor

Identifiers

PMID35476126
PMCPMC9278309
OpenAlexW4224995791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.